German psychophysiology SME specializing in human measurement and HCI evaluation for digital healthy ageing systems.
Institut für Experimentelle Psychophysiologie GmbH is a Düsseldorf-based private research company specializing in the measurement and analysis of physiological and psychological responses — think biometric monitoring, stress assessment, cognitive load testing, and behavioral measurement in applied settings. Their H2020 work places them squarely at the intersection of digital health and ageing: they contribute psychophysiological measurement expertise to systems designed to support older adults living independently. In both projects they joined, their role likely involved user testing, sensor-based data collection, or validating that digital coaching interfaces are actually usable and effective for elderly populations. The company name signals a lab-style operation with strong experimental methodology — they run studies, collect real human data, and translate psychophysiological signals into design or clinical insights.
The company's core identity as an experimental psychophysiology institute underpins both my-AHA and e-VITA, where physiological and behavioral data collection from human subjects is central.
Both projects — my-AHA (active and healthy aging) and e-VITA (virtual coach for smart ageing) — address the same domain of supporting older adults through technology.
HCI appears as a keyword in e-VITA (2021–2024), indicating involvement in interface design evaluation or usability testing for elderly users.
e-VITA lists personalized services as a keyword, suggesting contribution to adaptive or individualized coaching systems grounded in physiological data.
In the first project (my-AHA, 2016–2020) no detailed keywords were recorded, suggesting a broader or more foundational role in the active aging consortium — possibly contributing general psychophysiological testing capability without a specific thematic sub-focus. By the second project (e-VITA, 2021–2024), three precise keywords emerged: healthy ageing, personalized services, and human-computer interaction — indicating that their contribution became more defined and technology-facing over time. The shift points toward a maturing specialization: from general psychophysiology applied to ageing, toward the specific challenge of designing and validating personalized, human-centered digital interfaces for older populations.
They are moving deeper into the digital health layer — from measuring bodies to evaluating how older people interact with and benefit from AI-driven coaching systems, which positions them well for future projects combining wearables, virtual assistants, and age-appropriate UX.
They have participated exclusively as consortium partners across both projects and have never held a coordinator role — a consistent pattern for a specialist SME that brings a specific methodological contribution rather than project management capacity. With 25 unique partners across 12 countries from just two projects, they operate in broad, multi-partner international consortia typical of RIA (Research and Innovation Action) grants. This suggests they are experienced at integrating their work into large collaborative frameworks and are unlikely to seek or expect a lead role.
Despite only two projects, the organization has built a notably wide network of 25 unique partners spanning 12 countries — a breadth more typical of organizations with four or five projects. Their European footprint includes likely connections to Japanese partners via the e-VITA project (which explicitly named European-Japanese collaboration in its title).
This is one of very few private-sector psychophysiology labs active in EU-funded ageing research — most psychophysiology expertise in H2020 came from universities. Their private company structure means they can move faster than academic partners and offer commercial continuity for pilot studies or product validation phases. For a consortium building a digital health product for older adults, they offer the rare combination of experimental methodology, real human subject testing infrastructure, and SME flexibility — without the overhead of a hospital or university partnership.
